

References

1. <https://www.who.int/news-room/fact-sheets/detail/epilepsy>
2. Ghosh, S., Sinha, J. K., Ghosh, S., Sharma, H., Bhaskar, R., & Narayanan, K. B. (2023). A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management. *Brain Sciences*, 13(9), 1305. <https://doi.org/10.3390/brainsci13091305>
3. Kerr WT, Suprun M, Kok N, Reddy AS, McFarlane KN, Kwan P, Somerville E, Bagiella E, French JA. Factors associated with placebo response rate in randomized controlled trials of antiseizure medications for focal epilepsy. *Epilepsia*. 2025 Feb;66(2):407-416. doi: 10.1111/epi.18197. Epub 2024 Dec 21. PMID: 39707877; PMCID: PMC11827720.
4. Wesnes KA, Edgar C, Dean AD, Wroe SJ (2009). The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. *Epilepsy and Behaviour*. 14: 522-528. doi: 10.1016/j.yebeh.2008.11.012. Epub 2008 Dec 25.
5. Meador KJ, Yang H, Piña-Garza JE, Laurenza A, Kumar D, Wesnes KA (2016). Cognitive effects of adjunctive perampamil for partial-onset seizures: a randomized trial. *Epilepsia* 2016 Feb;57(2):243-51 doi: 10.1111/epi.13279